Quest Diagnostics Reports Strong Q1 Results, Raises Full-Year Revenue & EPS Guidance
DGX sits 26% above its 52-week low of $160.02 on elevated volume (2.0× avg).
Summary
Quest Diagnostics announced robust first-quarter 2026 financial results, with significant revenue and adjusted EPS growth, leading the company to raise its full-year 2026 guidance for both revenue and earnings per share.
Key Events · Earnings and Guidance · DGX
-
Reports Strong First Quarter 2026 Results
Quest Diagnostics reported Q1 2026 revenues of $2.90 billion, a 9.2% increase from the prior year, with adjusted diluted EPS rising 13.1% to $2.50.
-
Raises Full-Year 2026 Guidance
The company increased its full-year 2026 net revenue guidance to a range of $11.78 billion to $11.90 billion and adjusted diluted EPS guidance to $10.63 to $10.83, reflecting confidence in continued performance.
-
Advances Strategic Initiatives
Highlights include progress in Co-Lab Solutions, robust growth in consumer channels and Advanced Diagnostics (including Quest AD-Detect®), and the launch of an AI Companion tool for patients.
Analysis · DGX · Industrial Applications And Services
This 8-K filing confirms strong operational performance for Quest Diagnostics, with Q1 revenues up 9.2% and adjusted diluted EPS increasing by 13.1% year-over-year. The company's decision to raise its full-year 2026 revenue and EPS guidance signals management's confidence in continued growth and execution of its strategic initiatives. This positive financial update, following a news alert earlier today, provides comprehensive details that reinforce a positive outlook for the company.
At the time of this filing, DGX was trading at $201.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $21.6B. The 52-week trading range was $160.02 to $213.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.